International Ophthalmology

, Volume 17, Issue 4, pp 217–222 | Cite as

Intravitreal penetration of oral pefloxacin in humans

  • Murat Oncel
  • Gholam A. Peyman
Original Papers


We measured vitreous and serum levels of pefloxacin after oral administration. Twenty patients with retinal detachments undergoing vitrectomy were recruited into this study. Each patient received 400 mg pefloxacin orally 1 to 12 hours before vitrectomy. Vitreous fluid (0.1 mL) was aspirated at surgery. Vitreous levels of pefloxacin were determined by high-performance liquid chromatography. Six hours after oral administration, an average level of 1.37 μg/mL of pefloxacin was measured in the vitreous samples. These levels were well above the minimum inhibitory concentration (MIC) for most organisms termed sensitive to pefloxacin. Oral administration of pefloxacin may play an important role in the prevention or management of endophthalmitis.

Key words

endophthalmitis pefloxacin vitrectomy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Affeldt JC, Flynn HW Jr, Forster RK, Mandelbaum S, Clarkson JG, Jarus GD. Microbial endophthalmitis resulting from ocular trauma. Ophthalmology 1987; 94:407–13.Google Scholar
  2. 2.
    Axelrod JL, Klein RM, Bergen RL, Sheikh MZ. Human vitreous levels of cefamandole in moxalactam. Am J Ophthalmol 1986; 101: 684–7.Google Scholar
  3. 3.
    Axelrod JL, Klein RM, Bergen RL, Sheikh MZ. Human vitreous levels of selected antistaphylococcal antibiotics. Am J Ophthalmol 1985; 100: 570–5.Google Scholar
  4. 4.
    Axelrod JL, Kochman RS. Cefonicid concentrations in human aqueous humor. Arch Ophthalmol 1984; 102:433–4.Google Scholar
  5. 5.
    Axelrod JL, Newton JC, Klein RM, Bergen RL, Sheikh MZ. Penetration of imipenem into human aqueous and vitreous humor. Am J Ophthalmol 1987; 104: 649–53.Google Scholar
  6. 6.
    Barza M. Animal models in the evaluation of chemotherapy of ocular infections. In: Zak O, Sande MA (eds) ‘Experimental models in antimicrobial chemotherapy’. Vol. 1. Academic Press, London, pp 187–211, 1986.Google Scholar
  7. 7.
    Barza M. Factors affecting the intraocular penetration of antibiotics. Scand J Infect Dis 1978; 14:151.Google Scholar
  8. 8.
    Barza M. Use of quinolones for treatment of ear and eye infections. Eur J Clin Microbiol Infect Dis 1991; 10:296–303.Google Scholar
  9. 9.
    Barza M, Baum J. Ocular pharmacology of antibiotics. In: Duane TD, Jaeger EA (eds) ‘Biomedical foundations of ophthalmology’. Lippincott Co., Philadelphia, pp 1–14, 1987.Google Scholar
  10. 10.
    Barza M, Baum J, Birkby B, Weinstein L. Intraocular penetration of carbenicillin in the rabbit. Am J Ophthalmol 1973; 75: 307–13.Google Scholar
  11. 11.
    Barza M, Kane A, Baum J. Comparison of the effects of continuous and intermittent systemic administration on the penetration of gentamicin into infected rabbit eyes. J Infect Dis 1983; 147:144–8.Google Scholar
  12. 12.
    Barza M, Kane A, Baum J. Intraocular penetration of gentamicin after subconjunctival and retrobulbar injection. Am J Ophthalmol 1978; 85: 541–7.Google Scholar
  13. 13.
    Baum J, Peyman GA, Barza M. Intravitreal administration of antibiotic in the treatment of bacterial endophthalmitis. III. Consensus. Surv Ophthalmol 1982; 26: 204–6.Google Scholar
  14. 14.
    Brinton GS, Topping TM, Hyndiuk RA, Aaberg TM, Reeser FH, Abrams GW. Posttraumatic endophthalmitis. Arch Ophthalmol 1984; 102: 547–50.Google Scholar
  15. 15.
    Bron A, Talon D, Delbosc B et al. La pénétration intracamérulaire de la péfloxacine chez l'homme. J Fr Ophthalmol 1986; 9: 317–21.Google Scholar
  16. 16.
    Brumfitt W, Franklin I, Grady D, Hamilton-Miller JMT, Iliffe A. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother 1984; 26: 757–61.Google Scholar
  17. 17.
    Cochereau-Massin I, Bauchet J, Faurisson F, Vallois JM, Lacombe P. Pocidals JJ. Ocular kinetics of pefloxacin after intramuscular administration in albino and pigmented rabbits. Antimicrob Agents and Chemother 1991; 35:1112–5.Google Scholar
  18. 18.
    Cunha-Vaz J. Sites and functions of the blood-retinal barriers. In: Cunha-Vaz J (ed) ‘Blood-retinal barrier’. Plenum Press, New York, pp 101–117, 1980.Google Scholar
  19. 19.
    Dalhoff A, Weidner W. Diffusion of ciprofloxacin into prostatic fluid. Eur J Clin Microbiol 1984; 3: 360–2.Google Scholar
  20. 20.
    Denis F, Mounier M, Adenis JP. Etude de passage intra-oculaire de la péfloxacine chez l'homme et le lapin: Humeur aqueuse et vitré. Pathol Biol (Paris) 1987: 35: 772–6.Google Scholar
  21. 21.
    Duval J, Acar JF, Bergogne-Berezin E et al.In vitro activity of pefloxacin against 3422 hospital strains, a multicenter study. 13th International Congress of Chemotherapy, Vienna, PS 1983; 4: 6–2.Google Scholar
  22. 22.
    El Baba FZ, Trousdale MD, Gauderman WJ, Wagner DG, Liggett PE. Intravitreal penetration of oral ciprofloxacin in humans. Ophthalmology 1992; 99:483–6.Google Scholar
  23. 23.
    Faris BM, Uwaydah MM. Intraocular penetration of semisynthetic penicillins. Methicillin, cloxacillin, ampicillin, and carbenicillin studies in experimental animals with a review of the literature. Arch Ophthalmol 1974; 92: 501–5.Google Scholar
  24. 24.
    Ficker L, Peacock J. Infectious endophthalmitis. Trans Ophthalmol Soc UK 1986; 105: 319–23.Google Scholar
  25. 25.
    Forster RK. Postoperative endophthalmitis. Etiology and diagnosis of bacterial postoperative endophthalmitis. Ophthalmology 1978; 85: 320.Google Scholar
  26. 26.
    Forster RK, Abbott RL, Gelender H. Management of infectious endophthalmitis. Ophthalmology 1980; 87: 313–9.Google Scholar
  27. 27.
    Fourtillan JB. Comportement pharmacocinétique de la péfloxacine chez l'homme. Rev Med Interne 1986; 7:185–95.Google Scholar
  28. 28.
    Graham RO, Peyman GA, Fishman G. Intravitreal injection of cephaloridine in treatment of endophthalmitis. Arch Ophthalmol 1975; 93: 56–61.Google Scholar
  29. 29.
    Kasbeer RT, Peyman GA. Intravitreal oxacillin in experimental staphylococcal endophthalmitis. Graefes Arch Clin Exp Ophthalmol 1975; 1 96: 279–87.Google Scholar
  30. 30.
    Keren G, Alhalel A, Bartov E et al. The intravitreal penetration of orally administered ciprofloxacin in humans. Invest Ophthalmol Vis Sci 1991; 32: 2388–92.Google Scholar
  31. 31.
    Lafaix C, Salvanet A, Fisch A et al. Diffusion des fluoroquinolones dans l'humeur aqueuse et le cristallin. Pathol Biol (Paris) 1987; 35(5 Pt 2): 768–71.Google Scholar
  32. 32.
    Langham M. Factors affecting the penetration of antibiotics into the aqueous humor. Br J Ophthalmol 1951; 35: 614–20.Google Scholar
  33. 33.
    Lebel M, Bergeron MG. Pharmacokinetics in the elderly. Studies on ciprofloxacin. Am J Med 1987; 82(Suppl 4A): 108–14.Google Scholar
  34. 34.
    Lockley MR, Wise R, Dent J. The pharmacokinetics and tissue penetration of ofloxacin. J Antimicrob Chemother 1984; 14: 647–52.Google Scholar
  35. 35.
    Macllwaine WA, Sande MA, Mandell GL. Penetration of antistaphylococcal antibiotics into the human eye. Am J Ophthalmol 1974; 77: 589–92.Google Scholar
  36. 36.
    Montay G, Goueffon Y, Roquet F. Absorption, distribution, metabolic fate and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans. Antimicrob Agents Chemother 1984; 25: 463–72.Google Scholar
  37. 37.
    Montay G, Tassel JP. Improved high-performance liquid Chromatographic determination of pefloxacin and its metabolite norfloxacin in human plasma and tissue. J Chromatogr 1985; 339: 214–8.Google Scholar
  38. 38.
    Norrby SR. Side effects of quinolones: Comparisons between quinolones and other antibiotics. Eur J Clin Microbiol Infect Dis 1991; 10: 378–83.Google Scholar
  39. 39.
    Paque JT, Peyman GA. Intravitreal clindamycin phosphate in the treatment of vitreous infection. Ophthalmic Surg 1974; 5: 34–9.Google Scholar
  40. 40.
    Peyman GA, May DR, Ericson ES, Apple D. Intraocular injection of gentamicin: toxic effects and clearacne. Arch Ophthalmol 1974; 92:42–7.Google Scholar
  41. 41.
    Peyman GA, Nelson P, Bennett TO. Intravitreal injection of kanamycin in experimentallly induced endophthalmitis. Can J Ophthalmol 1974; 9: 322–7.Google Scholar
  42. 42.
    Peyman GA, Vastine DE, Meisels HI. The experimental and clinical use of intravitreal antibiotics to treat bacterial and fungal endophthalmitis. Doc Ophthalmol 1975; 39:183–201.Google Scholar
  43. 43.
    Peyman GA, Vastine DW, Raichand M. Postoperative endophthalmitis. Experimental aspects and their clinical application. Ophthalmology 1978; 85: 374.Google Scholar
  44. 44.
    Puliafito CA, Baker AS, Haaf J, Foster CS. Infectious endophthalmitis: Review of 36 cases. Ophthalmology 1982; 89: 921–9.Google Scholar
  45. 45.
    Records RE, Ellis PP. The intraocular penetration of ampicillin, methicillin, and oxacillin. Am J Ophthalmol 1967; 64: 135–3.Google Scholar
  46. 46.
    Rowsey JJ, Newsom DL, Sexton DJ, Harms WK. Endophthalmitis current approaches. Ophthalmology 1982; 89: 1055–66.Google Scholar
  47. 47.
    Rubinstein E, Goldfarb J, Keren G, Blumenthal M, Treister G. The penetration of gentamicin into the vitreous humor in man. Invest Ophthalmol Vis Sci 1983; 24: 637–9.Google Scholar
  48. 48.
    Rubinstein E, Treister G, Avni I, Schwartzkopf R. The intravitreal penetration of cefotaxime in man following systemic and subconjunctival administrations. Ophthalmology 1987; 94: 30–4.Google Scholar
  49. 49.
    Salvanet A, Fisch A, Lafaix G et al. Pefloxacin concentrations in human aqueous humor and lens. J Antimicrob Chemother 1986; 18:199–201.Google Scholar
  50. 50.
    Salvanet-Bouccara A, Moutay G, Fisch Aet al. Diffusion oculaire dans l'humeur aqueuse et le cristallin de la petloxacine apres administration orale repetee chez l'homme. J Fr Ophthalmol 1991; 14(4): 260–4.Google Scholar
  51. 51.
    Shockley RK, Fishman P, Aziz M, Yannis RA, Jay WM. Subconjunctival administration of ceftazidime in pigmented rabbit eyes. Arch Ophthalmol 1986; 104:266–8.Google Scholar
  52. 52.
    Swanson BN, Boppana VK, Vlasses PH, Rotmensch HH, Ferguson RK. Norfloxacin disposition after sequentially increasing oral doses. Antimicrob Agents Chemother 1983; 23: 284–8.Google Scholar
  53. 53.
    Wingender W, Graefe KH, Gau W, Förster D, Beerman D, Schacht P. Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur J Clin Microbiol 1984; 3: 355–9.Google Scholar
  54. 54.
    Wise R, Lockley M, Dent J, Webberly M. Pharmacokinetics and tissue penetration of enoxacin. Antimicrob Agents Chemother 1984; 26: 7–19.Google Scholar
  55. 55.
    Wise R, Lockley R, Webberly M, Adhami ZN. The pharmacokinetics and tissue penetration of enoxacin and norfloxacin. J Antimicrob Chemother 1984; 14(Suppl C): 75–81.Google Scholar
  56. 56.
    Wise R, Lockley RM, Webberly M, Dent J. Pharmacokinetics of intravenously administered ciprofloxacin. Antimicrob Agents Chemother 1984; 26: 208–10.Google Scholar
  57. 57.
    Wolff M, Regnier B, Daldoss M, Nkam M, Vachon F. Penetration of pefloxacin into cerebrospinal fluid of patients with meningitis. Antimicrob Agents Chemother 1984; 26:289–91.Google Scholar
  58. 58.
    Wolfson JS, Hooper DC; Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989; 2: 378–424.Google Scholar
  59. 59.
    Yannis RA, Rissing JP, Buxton TB, Shockley RK. Multistrain comparison of three antimicrobial prophylaxis regimens in experimental postoperativePseudomonas endophthalmitis. Am J Ophthalmol 1985; 100:404–7.Google Scholar

Copyright information

© Kluwer Academic Publishers 1993

Authors and Affiliations

  • Murat Oncel
    • 1
  • Gholam A. Peyman
    • 2
  1. 1.Ophthalmology Department, Cerrahpasa Medical SchoolIstanbul UniversityTurkey
  2. 2.LSU Eye CenterLouisiana State University Medical Center School of MedicineNew OrleansUSA

Personalised recommendations